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Abstract
 The development of novel biomarkers is an unmet need in chronic Purpose:
obstructive pulmonary disease (COPD). Arterial blood comes directly from the
lung and venous blood drains capillary beds of the organ or tissue supplied. We
hypothesized that there would be a difference in levels of the biomarkers
metalloproteinase 9 (MMP-9), vascular endothelial growth factor A (VEGF-A)
and interleukin 6 (IL-6) in arterial compared with venous blood. 
 Radial artery and brachial vein blood samples were taken Methods:
simultaneously in each of 12 patients with COPD and seven controls with
normal lung function. Circulating immunoreactive MMP-9, VEGF-A and IL-6
levels in serum were measured using quantitative enzyme-linked
immunosorbent assays. Results were compared using a Student’s paired t test.
The study was powered to determine whether significant differences in cytokine
levels were present between paired arterial and venous blood samples.  
 In the 12 patients with COPD, four were female, and age ranged Results:
53-85 years, mean age 69 years. Three patients in the control group were
female, with age range 46-84 years, mean age 64.7 years. In the COPD group,
three patients had mild, five moderate and four severe COPD. No significant
difference was found between arterial and venous levels of MMP-9, VEGF-A or
IL-6. 
 In this pilot study, levels of the measured biomarkers in arterial Conclusions:
compared with venous blood in both COPD patients and healthy controls did
not differ. This suggests that as we continue to chase the elusive biomarker in
COPD as a potential tool to measure disease activity, we should focus on
venous blood for this purpose.
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Chronic obstructive pulmonary disease (COPD) is a major public 
health issue, predicted to become the 3rd leading cause of mor-
tality in the United States1,2. At present, the Global Initiative for   
Obstructive Lung Diseases (GOLD) divides patients into catego-
ries of mild, moderate, severe and very severe based on the forced 
expiratory volume in 1 second (FEV1). This classification has been 
shown to predict outcome and has been pivotal in guiding treatment 
of the disease3.
The progression of COPD has classically been determined by the 
change of the FEV1 over time, usually measured over years. Indeed, 
the duration of the large trials that have evaluated the effect of phar-
macological or surgical benefits in patients with COPD have ranged 
from 2 to 4 years4–7. It follows that defining disease activity or   
response to therapy with validated biomarkers that reflect dis-
ease progression would make potential future interventions easier 
to evaluate. Several studies have reviewed the roles of different   
potential biomarkers in COPD8. Our group has recently shown that 
serum levels of interleukin 6 (IL-6) and tumor necrosis factor alpha   
(TNF alpha) were higher and matrix metalloproteinase 9 (MMP-9) 
and vascular endothelial growth factor (VEGF) lower in patients 
with severe and very severe COPD compared with smoker and non-
smoker controls without airflow obstruction9. Furthermore, the levels 
correlated with several phenotypic expressions of the disease including 
exercise capacity, quality of life, exacerbation and mortality9. Data from 
the ECLIPSE investigators, who studied a larger cohort of COPD 
patients, showed that several biomarkers correlated with baseline 
FEV1 but only one correlated with rate of decline in FEV1, the 
Clara-Cell Protein 16 (CC-16)10. While there is no question that a 
biomarker would be of great importance in COPD, the sample site 
having the greatest yield has not been clearly defined11.
Blood from the systemic circulation returns to the lung for gas   
exchange and, theoretically, the presence of biomarkers could be mod-
ified during the transient time blood spends in the pulmonary vessels. 
Arterial blood should provide a more direct window to events occur-
ring in the lungs than venous blood, which is perhaps more reflective 
of events happening in the capillary bed of the organ/tissues that it 
supplies. This is most evident in the significant differences that exist 
between arterial and venous blood gas measurements.
We conducted this pilot study to test the hypothesis that in patients 
with COPD (a primary disease of the lungs) there is a difference in 
serum concentrations of the biomarkers MMP-9, VEGF-A and IL-6 
between simultaneously collected arterial and venous blood. Fur-
ther, we compared the results with similar samples from patients 
without airflow obstruction that served as controls.
Materials and methods
Study population
This was a prospective pilot study. Samples were collected from 
patients attending the pulmonary clinic at St. Elizabeth’s Medical 
Center in Boston, Massachusetts. The study was approved by the 
Human Institutional Review Board of the institution and all patients 
signed the informed consent. The patients in the COPD group 
had smoking history ≥ 20 pack-years (1 pack year is equivalent to 
1 year at 20 cigarettes per day) and had post-bronchodilator FEV1/
FVC (forced vital capacity) ratio, < 0.7 after 400 µg of inhaled 
salbutamol. Patients had stable COPD and were not included if they 
had a history of an exacerbation in the last 3 months. The controls 
were patients attending the pulmonary clinic at the same institution 
with no history of COPD and normal lung function.
Clinical parameters
Age, gender, smoking history and body mass index (BMI) were   
recorded for every participant. All subjects performed a spirometry 
according to the American Thoracic Society (ATS) recommenda-
tions and standard references and severity of COPD was catego-
rized using GOLD staging. The BODE score is a composite score of 
BMI, degree of obstruction as recorded by FEV1, dyspnoea as quan-
tified by the modified Medical Research Council dyspnoea scale 
and exercise tolerance, as measured with a 6 minute walk test12.
Biomarker analysis
Simultaneous radial artery and antecubital venous samples were 
obtained in each participant. The blood samples were centrifuged 
immediately at 2500 rpm for 10 minutes and serum stored at -80ºC. 
Circulating immunoreactive MMP-9, VEGF-A and IL-6 levels in 
the serum were measured using commercially available quantita-
tive enzyme-linked immunosorbent assays (ELISA) (Human IL-6 
ELISA Ready-Set-Go! eBioscience, San Diego, CA; Human total 
MMP-9 DuoSet, R&D Systems, Inc. Minneapolis, MN; Human 
VEGF-A Platinum ELISA from eBioscience, San Diego, CA).
Statistical analysis
We worked out a power/sample size calculation based on the premise 
that this was a study of a continuous response variable from matched 
pairs of study subjects. Prior data indicated that the difference in the 
response of matched pairs is normally distributed with standard devia-
tion of 0.3 in the case of MMP-9 and VEGF-A, and 0.4 for IL-613. If 
the true difference in the mean response of matched pairs is 0.3, we 
would need to study 10 pairs of subjects to reject the null hypothesis 
with probability (power) of 0.8. If the true difference in the meanre-
sponse of matched pairs is 0.4, we would need to study 12 pairs of sub-
jects to be able to reject the null hypothesis with a probability (power) 
of 0.8. The Type I error probability associated with this test is 0.05.
Groups were compared using the Student’s t test for normally dis-
tributed variables and Mann-Whitney U test for variables not nor-
mally distributed. p ≤ 0.05 was considered statistically significant. 
Spearman’s rank order correlation coefficient was also used for 
non-parametric data. Statistical analysis was performed using a 
commercial statistical package (Sigma Stat, Sigma Plot).
Results
The characteristics of all participants are shown in Table 1. The 
twelve patients in the COPD group (4 female) ranged in age between 
53 and 85 years. Three had mild, five had moderate and four had   
severe COPD by the GOLD classification14. The seven patients (three 
females) included in the control group had normal lung function and 
their mean age range was similar to the COPD group (46–84 years). 
The majority of subjects in both groups were ex-smokers, with only 
3 patients in the control group being never-smokers.
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Normal Age 
(years)
Gender 
(Male-M, 
female-F)
Smoking history 
(Smoker-S, 
Non-smoker-NS, 
Ex-smoker- ExS)
FEV1 
(liters)
FEV1 
(% predicted) FVC FEV1/FVC Stage of 
COPD BMI
6 minute 
walk test 
(meters)
BODE 
score
1 46 M NS 4.79 128% 5.72 84 Normal 23 495 0
2 46 M NS 4.35 95% 5.88 74 Normal 28 690 0
3 66 F NS 1.79 83% 2.29 78 Normal 28.3 425 0
4 73 F ExS 2.33 109% 3.02 77 Normal 39 330 2
5 80 F ExS 2.16 95% 3.03 71 Normal 37 370 2
6 58 M ExS 2.59 87% 4.08 70 Normal – – –
7 84 M ExS 1.5 73% 2.13 70 Normal – Refused –
COPD
1 80 M ExS 2.24 85% 3.66 61 Mild 26.5 380 0
2 65 F ExS 2.23 87% 3.68 61 Mild 29 423 0
3 71 F ExS 2.11 104% 3.45 61 Mild 26.6 450 0
4 53 M S 2.33 68% 3.87 60 Moderate 27 505 0
5 68 M ExS 2.06 62% 4.43 46 Moderate 27.5 535 1
6 76 M ExS 1.71 60% 3.43 50 Moderate 34 403 1
7 85 M ExS 1.68 67% 2.42 68 Moderate 26.9 287 2
8 78  M ExS 1.6 62% 3.47 46 Moderate 27 460 1
9 66 F ExS 0.97 40% 2.47 40 Severe 28 505 2
10 65 M S 1.45 39% 4.69 31 Severe 29 377 2
11 57 M ExS 1.41 42% 3.36 42 Severe 33.9 431 3
12 64 F ExS 2.34 36% 2.78 63 Severe 33 362 2
Arterial and venous biomarker levels
MMP-9 (Figure 1): Serum MMP-9 levels were not normally dis-
tributed in all of the subjects (n = 19). The median venous MMP-9 
level was 40,706 pg/ml, (interquartile range 23,659–79,595 pg/ml). 
The median arterial level was 37,653 pg/ml (interquartile range 
21,833–64,351 pg/ml). There was no significant difference between 
the venous and arterial levels, p = 0.812. There was no difference 
between COPD and control levels of venous or arterial MMP-9. 
VEGF-A (Figure 2): In the 19 subjects, the VEGF-A levels in venous 
blood had a median value of 67.24 pg/ml, with interquartile range 
45.24 to 268.90 pg/ml whereas in arterial blood the median value was 
89.88 pg/ml, with interquartile range 58.90 to 239.38 pg/ml. There 
was no statistically significant difference between arterial and   
venous samples (p = 0.249). No significant difference was observed 
between patients with COPD and controls. 
IL-6 (Figure 3): IL-6 levels were undetectable in many of the 
subjects. The median venous level of IL-6 was 0, with an inter-
quartile range of 0 to 4.52 pg/ml and the median arterial level was 
also 0 pg/ml with an interquartile range of 0 to 3.61 pg/ml. There 
was no statistically significant difference (p = 0.986) between 
venous and arterial levels of this cytokine. As levels of IL-6 
were undetectable in many of the patients, it was not possible to   
determine if a significant difference existed between those with 
COPD and the control group.
Discussion
This pilot study showed no difference in serum levels of MMP-9, 
VEGF-A or IL-6 between arterial and venous blood samples in a 
group of patients with COPD and controls without airflow obstruc-
tion. Our results indicate no advantage of obtaining arterial over 
venous samples for the determination of these biomarker levels in 
patients with COPD.
At present, the most important determinant of COPD severity and pro-
gression is the FEV1 value and its progression over time, usually meas-
ured in years. This approach has its limitations and fails to account for 
the so-called activity of the disease15. As more treatments for COPD 
are emerging, the importance of biomarkers that reflect disease   
activity becomes paramount. A biomarker, by definition, is “any mole-
cule or material (e.g. cells and tissues) that reflects the disease process”16.   
Because of its ease of accessibility, work has focused on peripheral 
blood biomarkers. Many have been investigated with initial work show-
ing C reactive protein (CRP) levels to be associated with degree of air-
way obstruction, although subsequent work in patients with moderate 
to severe COPD found no relationship between CRP levels and reduced 
survival17–19. Other promising biomarker candidates previously studied 
include circulating levels of Clara cell secretory protein-16 (CC-16)20, 
surfactant protein (SP)-D21 and serum amyloid A (SAA)22. Serum levels 
of CC-16, a marker of Clara cell toxicity, are reduced in patients with 
COPD10, while SP-D is increased in smokers with and without COPD21, 
and SAA may be a potential biomarker of COPD exacerbation22.
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in arterial blood in COPD patients. Studies where arterial ves-
sels are accessed for cardiopulmonary bypass or for extracorpor-
eal liver support have measured arterial blood levels of various 
cytokines but only within narrow inclusion criteria, and arterial 
and venous level comparisons were not published23,24. In a study 
of the effect of moderate hypothermia on systemic and internal 
jugular plasma IL-6 levels after traumatic brain injury in humans, 
IL-6 was found to be significantly higher in internal jugular venous 
blood than in arterial plasma25. In the setting of recent neuro-trauma 
this is understandable. Having stressed the importance of suitable   
potential biomarkers in COPD, we hypothesized that determining the  
optimal source of the sample could be of potential value. Our most 
important finding was that for the biomarkers studied, levels did 
not differ between arterial and venous samples. This was not due 
to the nature of the biomarkers selected because the markers we 
investigated in this study were chosen based on prior work demon-
strating the level of IL-6 was higher and MMP-9 and VEGF levels 
lower in patients with more advanced COPD compared with con-
trols9,26,27. Although the host response to insult is, to a large extent, 
compartmentalized to the affected lung, cytokine spillover into the 
systemic circulation has been shown to occur10,28 and be measur-
able in the systemic circulation10,28. We did not find differences in 
serum biomarker levels between patients with COPD and those 
without airflow obstruction; however, the study was not powered 
to explore this hypothesis.
Our pilot study has some limitations. First, the number of patients 
recruited could be considered small, but it was powered to address 
whether there was a difference between arterial and venous lev-
els of MMP-9, VEGF-A and IL-6. The use of matched samples   
allowed for accurate interpretation of the results with these subject 
numbers. Second, the blood samples were drawn from the radial 
artery and from a peripheral antecubital vein. Possibly, to obtain 
more accurate sampling of blood immediately leaving the lung, 
pulmonary arterial sampling would have been optimal. However, 
sampling of central venous blood is invasive and would not offer 
any practical advantage. Third, it is possible that the 3 selected ana-
lytes are not “exclusively” produced in the lung (as it is the case 
for SPD and CC16) and represent the systemic compartment and 
not just the lung milieu. This possibility requires the simultaneous 
measurement of these biomarkers in future studies. 
In summary, this pilot study shows that there was no difference 
in levels of MMP-9, VEGF-A or IL-6 when measured in blood 
samples from the radial artery compared with peripheral venous 
Figure 1. Total human MMP-9 levels were compared between 
paired samples of venous and arterial blood from COPD patients 
and normal controls. No difference was found (p = 0.812). Pairing 
of the two groups was shown to be effective with rs (Spearman, 
Approximation) 0.8782 and p<0.0001.
Figure 2. VEGF-A levels were compared between paired samples 
of venous and arterial blood from COPD patients and normal 
controls. No difference was found (p = 0.550). Pairing of the two 
groups was shown to be effective with rs (Spearman, Approximation) 
0.7526 and p = 0.0001.
Figure 3. IL-6 levels were compared between paired samples 
of venous and arterial blood from COPD patients and normal 
controls. No difference was found (p = 0.986). Pairing of the two 
groups was shown to be effective with rs (Spearman, Approximation) 
0.9966 and p<0.0001.
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biomarker in COPD as a potential tool to measure disease activ-
ity, focusing on venous blood for this purpose remains a valid 
option. 
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Thank you for taking the time to review our work. We acknowledge the limitations of this work and
agree that there would be advantages to taking pulmonary arterial samples to give more
physiological data. We share your concerns that the peripheral arterial sample may better reflect
the occurrences in the distal capillary bed and we have raised these issues in the discussion. We
were endeavouring to investigate the site of biomarker testing that could be used in real-life clinical
scenarios and therefore chose radial arterial sampling. Serum was the tested sample in this study.
Future work could give answers for these remaining physiological questions. 
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